Form 4: GeneDx CEO's Future Share Sale for Tax Obligations

GeneDx Holdings Corp. CEO Katherine Stueland reported a pre-planned future sale of shares on October 29, 2025, to cover tax withholding obligations from restricted stock unit vesting.

Summary

• Katherine Stueland, Chief Executive Officer and Director of GeneDx Holdings Corp. (WGS), reported transactions scheduled for October 29, 2025.
• These transactions are made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• She will acquire 3,874 shares of Class A Common Stock upon the settlement of Restricted Stock Units (RSUs) for no consideration.
• Concurrently, she will dispose of 2,154 shares of Class A Common Stock at a price of $136.54 and 4 shares at $136.75 to cover tax withholding obligations related to the RSU vesting.
• Following these reported transactions, her direct beneficial ownership will be 3,436 shares of Class A Common Stock.
• Additionally, she will beneficially own RSUs representing contingent rights to receive up to 440,665 shares of Class A Common Stock and options to purchase up to 107,610 shares of Class A Common Stock, which vest according to their respective terms.

Sentiment

Score: 6

Explanation: The filing reports a routine, pre-planned insider transaction for tax purposes related to RSU vesting, which is generally neutral. The vesting itself is a positive sign of continued service, but the sale reduces direct equity.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates continued service by the CEO, aligning management's interests with long-term shareholder value.
• The reported sale of shares is pre-planned under a Rule 10b5-1 plan, which reduces concerns about opportunistic or discretionary insider selling.

Negatives

• The sale of shares, even for tax purposes, results in a reduction of the CEO's direct equity stake in the company.

Future Outlook

The remaining RSUs and options held by Katherine Stueland are scheduled to vest according to their respective terms, with the final tranche of the reported RSU award vesting on April 29, 2026, subject to her continued service to the Issuer.

Management Comments

• The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a discretionary transaction.

Industry Context

This is a routine insider transaction disclosure common across all industries, reflecting standard executive compensation practices involving equity awards and subsequent tax obligations upon vesting.

Stakeholder Impact

• Shareholders: A minor reduction in the CEO's direct equity ownership due to tax-related sales, but the overall equity incentive structure remains in place. The pre-planned nature under Rule 10b5-1 mitigates concerns about discretionary selling.
• Employees: The RSU vesting demonstrates the company's equity compensation structure for executives.

Next Steps

• Continued vesting of Katherine Stueland's remaining RSUs and options according to their respective terms.
• The final tranche of the specific RSU award mentioned is scheduled to vest on April 29, 2026.

Key Dates

Keywords

GeneDx Holdings Corp, WGS, Katherine Stueland, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Tax Withholding, Equity Compensation, Rule 10b5-1